'With Essential3, we've developed a decentralized trial program unlike any other in ET, and among the first in the industry,' said
Praxis at AAN 2024 |
Connect with members of our team at booth #1834 or head to one of our presentations listed below where we will share updates on our journey to develop a new ET therapy.
P3003: An Innovative Multi-Study Phase 3 Program to Evaluate the Efficacy and Safety of Ulixacaltamide: The Future of Clinical Trial Design in Essential Tremor
A poster presentation showcasing Praxis novel registrational study design
Emerging Neurologic Care Industry Presentation: Essential3: An Innovative, Decentralized Phase 3 Essential Tremor Program
An industry platform presentation highlighting updates on Praxis' Phase 3 registrational program
S30.010: Assessing Clinically Meaningful Improvement Associated with Ulixacaltamide Treatment in Adults with Essential Tremor on Concomitant Propranolol: Findings from Essential1
An oral presentation demonstrating potential benefit of ulixacaltamide over propranolol
Selected materials will be made available on the Resources page of Praxis' website following presentation at AAN 2024: https://praxismedicines.com/resources/.
About Ulixacaltamide
Ulixacaltamide is a differentiated and highly selective small molecule inhibitor of T-type calcium channels designed to block abnormal neuronal burst firing in the Cerebello-Thalamo-Cortical (CTC) circuit correlated with tremor activity. Ulixacaltamide, the most advanced program within Praxis' Cerebrum small molecule platform, is currently in development for the treatment of essential tremor.
About Praxis
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws, including express or implied statements regarding Praxis' future expectations, plans and prospects, including, without limitation, statements regarding the development of Praxis' product candidates and the potential therapeutic effects of Praxis' product candidates, as well as other statements containing the words 'anticipate,' 'believe,' 'continue,' 'could,' 'endeavor,' 'estimate,' 'expect,' 'anticipate,' 'intend,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'seek,' 'should,' 'target,' 'will' or 'would' and similar expressions that constitute forward-looking statements under the Private Securities Litigation Reform Act of 1995.
The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation: uncertainties inherent in clinical trials; the expected timing of clinical trials, data readouts and the results thereof, and submissions for regulatory approval or review by governmental authorities; regulatory approvals to conduct trials and other risks concerning Praxis' programs and operations as described in its Annual Report on Form 10-K for the year ended
Contact:
Email: investors@praxismedicines.com
Tel: 857-702-9452
Email: cknight@lifescicomms.com
Tel: 713-582-0681
(C) 2024 Electronic News Publishing, source